Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 11/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 10/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120305 | 0.91 | MDM2 (0.36) | SLC16A3SLC16A1HTR2CSLC6A4HTT | |
| SCHEMBL3708988 | 0.89 | SLC16A3 (0.40) | SLC16A3SLC16A1HTR2CSLC6A4HTT | |
| SCHEMBL4119113 | 0.89 | ALDH1A1 (0.33) | HTR2CSLC6A4MAPTLMNACNR1 | |
| SCHEMBL3701898 | 0.87 | HTR2C (0.49) | SLC16A3SLC16A1HTR2CSLC6A4MAPT | |
| SCHEMBL4131517 | 0.87 | GPBAR1 (0.33) | HTR2CSLC6A4HTTLMNAMEN1 | |
| SCHEMBL4135340 | 0.87 | CNR1 (0.36) | SLC16A3SLC16A1HTR2CSLC6A4HTT | |
| SCHEMBL2838662 | 0.86 | SLC16A3 (0.38) | SLC16A3SLC16A1HTR2CSLC6A4MEN1 | |
| SCHEMBL3701902 | 0.86 | SLC16A3 (0.38) | SLC16A3SLC16A1HTR2CSLC6A4MAPT | |
| SCHEMBL4134984 | 0.85 | SLC16A3 (0.36) | SLC16A3SLC16A1HTR2CSLC6A4HTT | |
| SCHEMBL4140873 | 0.84 | SLC16A3 (0.40) | SLC16A3SLC16A1HTR2CSLC6A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC16A3 2809/4885SLC16A1 2925/4885HTR2C 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.